Company intelligence / Profile preview
BioQingLam
- Ownership
- Private
- Development stage
- Other
Overview
BioQingLam specializes in the research, development, and industrialization of soluble microneedle drug delivery technology. The company has demonstrated successful preclinical delivery of DNA vaccines using its proprietary platform and collaborates with several listed pharmaceutical companies to develop a range of microneedle-delivered products including genetic/inactivated vaccines, proteins, peptides, and chemical drugs. It operates the world’s first sterile GMP plant for soluble MN TDDS with global regulatory compliance capabilities.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Soluble microneedle drug delivery systems (MN TDDS)Gene drugs (including DNA vaccines)Proteins and polypeptidesChemical drugs
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on BioQingLam.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioQingLam.